News for 'CTIX' - (Cellceutix to Pursue Significant

New Post Public Reply Private Reply Replies (2) Message Board

Nov 4, 2013 at 7:15 AM

News for 'CTIX' - (Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin)

BEVERLY, MA, Nov 04, 2013 (Marketwired via COMTEX) -- Cellceutix Corporation
(OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company
developing innovative therapies in oncology, dermatology, and antibiotic
applications, is pleased to inform shareholders that the Company is conducting
experiments on Brilacidin(TM), its lead antibiotic compound, for ophthalmic
infections, including keratitis and conjunctivitis. Cellceutix estimates the
market potential for these indications well in excess of $1 billion and has its
antibiotic team expanding upon the significant amount of preclinical research
that has been conducted on Brilacidin for these conditions.

Prior to the Cellceutix acquisition of PolyMedix in September, lab studies
conducted at the Charles T. Campbell Ophthalmic Microbiology Laboratory at the
University of Pittsburgh demonstrated the safety, tolerability and broad
activity of Brilacidin against clinically important Gram-positive and
Gram-negative pathogens, including drug-sensitive and drug-resistant clinical
isolate strains of ocular infections.

Pharmacokinetic studies were conducted at Iris Pharma, a Contract Research
Organization based in France, showing that Brilacidin has a high residence time
on the surface of the eye with negligible systemic exposure. This indicates that
effective therapeutic concentrations of Brilacidin can be maintained in the eye
with infrequent treatments.

As a defensin-mimetic, Brilacidin is a completely novel class of antibiotics and
a platform for a broad spectrum of indications in an area of urgent need for new
drugs. Topical ophthalmic anti-infective drugs that are used today for keratitis
and conjunctivitis have serious limitations due to bacterial resistance and
serious side effects. For example, although exclusive of topical uses of
fluoroquinolones for eye and ear infections, the U.S. Food and Drug
Administration in August required that drug labels and Medication Guides for all
systemic fluoroquinolone antibacterial drugs be updated to describe the
potential serious side effect of peripheral neuropathy.

"The Brilacidin ocular data is highly exciting. Our new research program
focusing on ocular drugs is the next step in expanded uses of Brilacidin that we
believe will develop into a blockbuster antibiotic drug franchise," said Dr.
Krishna Menon, Chief Scientific Officer at Cellceutix. "We have a litany of
clinical and preclinical data on Brilacidin. Our research staff is currently
growing epithelial cells for testing so that we can formulate Brilacidin as a
topical solution with efficient penetration of the epithelium to maximize
clinical results."

"We are going to continue aggressively moving forward with Brilacidin as the
current biotechnology environment is desperate for new therapeutics," added Leo
Ehrlich, Chief Executive Officer at Cellceutix. "Reuters reported only yesterday
that Swiss drugmaker Roche is poised to get back into antibiotics because of a
novel drug that they want to develop to tackle drug-resistant bacteria. Simply,
a novel drug has phenomenal sales potential. Johnson & Johnson's Levaquin was
generating $1.3 billion in sales before it came off patent. Cubist's Daptomycin
for ABSSSI only comprised 8 percent of total doses, yet controlled approximately
82 percent of total sales in that market. The majority of approved antibiotics
today are legacy drugs or variations of them for which resistance is constantly
evolving. Our plan is to establish Brilacidin as the next generation antibiotic.
It has opened a door to a multi-billion-dollar pathway and we are not just
looking at it, we are part way through it and moving as quickly as possible to
establish a leadership position."

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company
under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical
company developing innovative therapies in oncology, dermatology and antibiotic
applications. Cellceutix believes it has a world class portfolio of compounds
and is now engaged in advancing its compounds and seeking strategic
partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1
clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth
Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce
activation of p53, often referred to as the "Guardian Angel Gene" due to its
crucial role in controlling cell mutations. Cellceutix is planning a Phase 2
clinical trial with its novel compound Brilacidin-OM for the prevention and
treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound has
shown in the laboratory to reduce the occurrence of severe ulcerative oral
mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug
Prurisol is being readied for a Phase 2/3 clinical trial at sites in the U.S.
and Europe. Prurisol is a small molecule that acts through immune modulation and
PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is set to begin a
Phase 2b trial in the first half of 2014 for Acute Bacterial Skin and Skin
Structure Infections, or ABSSSI. Brilacidin has the potential to be a
single-dose therapy for multi-drug resistant bacteria or a dosing regimen that
is shorter than currently marketed antibiotics. Cellceutix has formed research
collaborations with world renowned research institutions in the United States
and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical
Center, and the University of Bologna. More information is available on the
Cellceutix web site at www.cellceutix.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and assumptions that could cause Cellceutix's
actual results and experience to differ materially from anticipated results and
expectations expressed in these forward looking statements. Cellceutix has in
some cases identified forward-looking statements by using words such as
"anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar expressions. Among
other factors that could cause actual results to differ materially from those
expressed in forward-looking statements are Cellceutix's need for, and the
availability of, substantial capital in the future to fund its operations and
research and development; including the amount and timing of the sale of shares
of common stock to Aspire Capital; the fact that Cellceutix's compounds may not
successfully complete pre-clinical or clinical testing, or be granted regulatory
approval to be sold and marketed in the United States or elsewhere. A more
complete description of these risk factors is included in Cellceutix's filings
with the Securities and Exchange Commission. You should not place undue reliance
on any forward-looking statements. Cellceutix undertakes no obligation to
release publicly the results of any revisions to any such forward-looking
statements that may be made to reflect events or circumstances after the date of
this press release or to reflect the occurrence of unanticipated events, except
as required by applicable law or regulation.

Contact:

INVESTOR AND MEDIA CONTACT:

Cellceutix Corp.

Leo Ehrlich

(978) 236-8717

Email Contact

SOURCE: Cellceutix

(C) 2013  Marketwire L.P.  All rights reserved.

-0-

SUBJECT CODE:     Pharmaceuticals and Biotech:Biotech

                  Pharmaceuticals and Biotech:Trials

                  Pharmaceuticals and Biotech:Equipment and Supplies

                  Pharmaceuticals and Biotech

rugs

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MiniTool MovieMaker 8.9: Keyframe Animation Upgrade

Breaking Down MiniTool MovieMaker 8.9's Revamp Kicking off the day with some noteworthy news in the creative software arena, MiniTool's latest update to its MovieMaker program is grabbing attention. It’s not often you hear software developers hitting the right balance between functionality and simplicity as they've done with this release. Keyframe Animation: The Star of...

Dreame Unveils Vast AI Product Range at IFA 2026

Overnight Sensation or Future Staple? I wonder if Dreame's top brass woke up sweating or smiling after their big reveal at IFA 2026. A buffet of over 100 products across 16 categories is no small feat, especially when you're banking on technologies developed over nine years. But let's cut through the noise—does this showcase promise innovation or just smoke and mirrors?...

Carles Puyol Joins Midea at IFA 2026, Celebrating Unity

Leadership, Innovation, and Soccer Collide in Berlin When you’ve got a Barcelona legend like Carles Puyol gracing an event, it's more than just fanfare. This time around, Puyol made waves at Midea's stand during IFA 2026 in Berlin, signaling a strategic power move for both Midea and FC Barcelona. We're talking about a scene where tech innovation meets world-class...

BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Sarepta Under Scrutiny: KSF's Investigation Deepens

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Hyundai's Revolutionary US Steel Mill Set for 2029 Rollout

Hyundai's Major Steel Move: A Multibillion-Dollar Stake The steel industry scene in the U.S. just got a lot hotter with Hyundai's announcement of a $5.8 billion Electric Arc Furnace-based integrated steel mill in Louisiana. This game-changing project isn’t just a headline; it’s a concrete step towards beefing up the U.S. manufacturing backbone. Talk about...

Hims & Hers Faces Lawsuit as FTC Alleges Privacy Breach

FTC Cracks Down on Hims & Hers Privacy Practices Most folks don't wake up wanting to find their investments tangled in legal drama. But here we are with Hims & Hers Health (NYSE: HIMS), facing fire from the Federal Trade Commission (FTC). They’re being called out for allegedly spilling the beans on users' sensitive health data—something they claimed to keep under...

LG's High-Purity RGB Displays Shine at IFA 2026

LG's Latest Dazzler: RGB Evo Takes the Spotlight LG has never been shy about setting standards in the home entertainment sector, and they’re doing it again at IFA 2026 with their high-purity RGB displays. Make no mistake, when LG rolls out a massive LCD TV certified by TÜV Rheinland for color purity, every other home theater manufacturer is scrambling to keep up. "LG...

York Space Systems Faces Class Action Headwinds

York Space Systems: Under Legal Fire You ever hear the one about York Space Systems? Yeah, their ticker YSS is buzzing for all the wrong reasons. Not even a year out from their IPO, and already they're tangled in a class action lawsuit that's got investors with their heads in their hands. ClaimsFiler, a shareholder information outfit, just blasted out a reminder for...

Dynamic Automotive’s Car Show: Connecting Cars & Community

Cars, Community, and Cause Today’s dialogue isn’t about upcoming IPOs or blue-chip stocks, it's about classic cars rolling into the spotlight for something bigger than horsepower or polish. On Sunday, September 27, from noon till three, Dynamic Automotive will host its 18th Annual Car Show in Urbana, Maryland. They’re not just showing off vintage steel; they’re...